Colorectal Cancer Diagnosis and Therapeutic Updates E-Book
35,66 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
Colorectal Cancer is a complex disease caused by the interaction of hereditary and environmental factors that can be classified based on their importance. Colorectal Cancer Diagnosis and Therapeutic Updates provides comprehensive information about the diagnosis and treatment of colorectal cancer. Chapters first cover the fundamentals of colorectal cancer diagnosis, progressing further towards explaining therapeutic modalities and recent advances in the understanding of the disease.
Key Features
- 11 organized, reader-friendly chapters that provide a complete overview of colorectal cancer
- Covers the colorectal cancer diagnosis, screening and histopathology
- Covers multimodal treatment of colorectal cancer, including chemotherapy, radiotherapy and robotic surgery
- Covers the management and surveillance of colorectal cancer
- Explains the key biochemical mechanisms involved in colorectal cancer treatment
- Covers recent information about colorectal cancer theranostics and drug delivery
- Includes references for further reading in every chapter
The book serves as an introductory reference for medical students and residents on the subject of colorectal cancer. It also serves as a quick reference on the disease for the practicing general physician.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 215
Veröffentlichungsjahr: 2002
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
FOREWORD
Given the gap in the comprehensive book on “Colorectal cancer diagnosis and therapeutic updates, and the new findings”, the writers agreed to discuss as many key issues regarding colorectal cancer, its management, and therapeutic progress as necessary. This book is also unique in that it contains new information about IncRNA NLIPMT inhibitors and therapeutic use in the treatment of colorectal cancer. Another reason is the presence of several detailed chapters as well as a large number of appropriate illustrations. It is anticipated that after reading this book, the reader would have acquired the requisite skills for colorectal cancer diagnosis and clinical management. Knowing the signalling mechanisms involved in colorectal cancer targeting will open up fresh possibilities for cancer study in the reader's mind. Researchers and readers interested in finding a cure for colorectal cancer can read this book, according to the authors. The authors, in my view, will be fortunate to have grateful readers who obtain extensive expertise for their current practise in colorectal cancer treatment and therapeutics, as well as for future research.
Vineet Kumar Rai Department of Pharmaceutics ISF College of Pharmacy, Moga Punjab IndiaPREFACE
Cancer is a disease in which cells develop abnormally and may involve any part of the body. Cancer is distinguished by the sudden development of irregular cells. It spreads to other areas of the body and eventually to other organs; this is referred to as metastasizing. The most common cause of cancer-related death is metastasis. According to a World Health Organization (WHO) survey, about 9.6 million deaths were reported worldwide in 2018, and 7.6 million deaths were estimated in 2008 due to cancer. Lung, breast, colorectal, stomach, and liver cancers are some of the more prevalent cancers diagnosed in men. Breast cancer, colorectal cancer, lung cancer, cervical cancer, and thyroid cancer are some of the more prevalent cancers among women. Changing one's lifestyle and adopting more sustainable habits could prevent about 30 percent of cancer deaths. According to a study released on September 12, 2018 in "A Cancer Journal for Clinicians" by the International Agency for Research on Cancer (IARC), the top three cancer forms are prostate, female breast, and colorectal cancer, both of which are mainly present in humans. Colorectal cancer is the third most commonly diagnosed cancer (1.8 million patients, or 10.2 percent of all cases), followed by prostate cancer (1.3 million cases, or 7.1 percent), and stomach cancer (the fifth most commonly diagnosed cancer) (1.0 million cases, 5.7 percent). Per year, it is projected that 1.2 million people are diagnosed with colorectal cancer.
Colorectal cancer (CRC) is a complex disorder caused by the interaction of hereditary and environmental causes, which can be classified according to the importance of each of these factors. CRCs are often seasonal (70-80%), with age being the most important risk factor; hereditary variants account for just a small percentage of incidents. Colorectal cancer develops as a result of the accumulation of hereditary and epigenetic modifications. The most advanced CRCs grow from adenomas (adenoma-carcinoma sequence). The neoplastic transfer cycle is estimated to be about 10-15 years, which refers to the amount of time required to detect and remove these adenomas before they progress to invasive carcinoma. The three main carcinogenesis pathways for colorectal cancer (CRC) are currently being debated.
This book reflects on the most basic clinical and medical methods for colorectal cancer care. Furthermore, we concentrate on recent advancements in colorectal cancer science as well as the critical mechanisms involved in colorectal cancer treatment.
The chapters of this book are structured in such a manner that even readers with no prior awareness of the topic will learn about it in the book. As a result, the book's contents have been divided into eleven chapters.
We did our best to include relevant knowledge in a clear and concise manner. We hope that by the end of the book, readers will be able to follow other researchers in their pursuit of the topic's estimated supremacy. Furthermore, we hope to be able to contribute to the development of research in this area.
Sankha Bhattacharya Associate Professor, Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, IndiaAmit Page Assistant Professor, Department of Pharma Science, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, IndiaSaurabh Maru Assistant Professor, Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India &Shilpa Dawre Assistant Professor, Department of Pharmaceutics, School of Pharmacy & Technology Management,ACKNOWLEDGEMENT
We would like to convey our heartfelt appreciation to God Almighty for always being gracious and supportive to us. He offered us the chance to thrive and immerse ourselves in His unique molecular universe, which are gifts that only a few humans have seen. We humbly express our gratitude to our families for their patience and generosity throughout the writing of this novel. We would like to extend our heartfelt thanks to all those people who helped us along the way. This book is for those who want to expand their expertise in the area of cancer and keep themselves up to date.
Sankha Bhattacharya Associate Professor, Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, IndiaAmit Page Assistant Professor, Department of Pharma Science, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, IndiaSaurabh Maru Assistant Professor, Department of Pharmacology, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India &Shilpa DawreList of Contributors
Colorectal Cancer Diagnosis
Sankha Bhattacharya1,*,Amit Page1,*,Kapil Gore1,*,Amaiyya Agrawal1,*Abstract
A diagnosis is an important tool in the detection and combat of colorectal cancer. Early-diagnosed cancer can be cured easily. There are many invasive as well as non-invasive methods of diagnosis for colorectal cancer. Non-invasive methods usually involve the use of various biomarkers for diagnostic purposes. Recently, enzymes from lysosomes that take part in metastases have been discovered to have importance as a diagnostic tool.
INTRODUCTION
Colorectal cancer is the third leading cause of death from cancer. It is observed that almost 4.3% of men and 4.0% of women in this world is suspectable to have colorectal cancer in upcoming times. The outcome for people with colorectal cancer is improving, but the overall five-year survival rates are still lower than 60%. There is a need for greater accuracy in diagnosis and staging. The astonishing fact about colorectal cancer (CRC) is that among all the colorectal cases, almost half the percentage is reported from developing countries. This might be due to the limited resources for diagnosis and poor health infrastructure, which ultimately leads to increased mortality rates due to CRC. Though, in western countries, the good health infrastructure and early screening and diagnosis improvise CRC treatment. As far as India is concerned, the age standard rate (ASR) for CRC cases is low, approximately 7.2 per 100,000 male population and 5.1 per 100,000 female population; yet India is a nation of 1.38 billion-plus people, with a staggering number of CRC-affected populations, and with a low five-year survival rate (less than 40%) [1].
Certain epigenetic disorders and genetic alterations can hinder CRC treatment. The basic reason for CRC is the methylation and covalent modification of histones. To make treatment of CRC more effective, early diagnosis of neoplasms and identification of pre-cancerous stageis essential [2]. It hasbeen observed from histological data that CRC can cause perforation within the intestine; therefore, chances of obstructive ileus formation are pragmatic.Most of the patients, who witnessed colonic polyps at early stages, ultimately develops CRC. It is of utmost importance to remove adenomatous polyps to prevent the conversion of CRC from colonic polyps (Fig. (1) [3].
Fig. (1))(A) Developmental process of nonpolypoid colorectal neoplasms; (B). Macroscopic classification of colorectal neoplasms; (C). Submucosal invasion.Invasive Examination
To identify the CRC, the most common practice is rectal examination. During the examination, almost around 70% rectal and 30% CRCs can be diagnosed. But it is most important to have the necessary experience as a physician who handles the case. Endoscopy is the most prominent tool or method to instantly recognize CRC.
To perform the histological examination and to perfectly identify and localize tumors associated with CRC, it is important to perform sigmoidoscopy and colonoscopy, which are a type of endoscopy [4]. With the help of recent advancements in endoscopy, it is possible to detect tumors with up to 92-97% accuracy. If there is an advancement of CRC to lower parts of the colon, then sigmoidoscopy can play a pivotal role in diagnosing the condition, whereas colonoscopy helps to inspect the entire colon with the proper illustration of sensitive information. During the diagnosis of CRC, the colonoscopy was found to have many advantages, viz., it can increase the accuracy of detection with a limited time frame. To perform the palliative procedure and CRC diagnosis sigmoidoscopy would be a necessary tool. For those patients, who are at potential risk if the surgical operation is performed, sigmoidoscopy can help to clean and identify obstructions generated due to CRC. The biggest disadvantage of sigmoidoscopy is its invasive operations, which can create certain discomfort to the patients; as it may create preformation and bleeding in the intestine [5]. Lead to circumvent such problems, recently developed virtual colonoscopy created a buzz within the scientific community. By applying computer tomography, it is possible to obtain 3D images of the large intestine. Most importantly, the non-invasive virtual colonoscopy helps to decrease the risk of unnecessary bleeding from the intestine [6]. Many imaging tests like nuclear magnetic resonance (NMR), endorectal ultrasonography (USG) help to identify the actual conditions of CRC when the patient has severe focal lesions. From the biomedical research, it was found that, alternation of carbohydrate, fluor-18-fluorodeoxyglucose positron could be the reason for CRC. The positron emission computed tomography (18F-FDG PET/CT) depicts a prognostic value with response to the treatment. The 18F-FDG PET/CT tomography helps to identify the potential chemotherapeutic challenges in patients, who are affected with CRC. From the ongoing research, it was observed that 18F-FDG-PET/CT has a significant amount of CT sensitivity; which allows researchers to identify cancer metastases within the liver. Many pieces of research suggest that positron emission tomography (FDG PET) was found to be the most potent tool to identify the interpreted results from gastrointestinal stromal tumours. The treatment using 18F-FDG-PET/CT has shown positive responses within 10 days of the initialization of treatment. This technique is more effective in patients after radio-chemotherapy. As per the NICE guidelines 27, if the body persists lesion, colonoscopy is recommended.
NON-INVASIVE DIAGNOSIS METHODS
Fecal Occult Blood Test
In this technique, the hemoglobin content was identified in human fecal. If traces of hemoglobin are found, it indicates that the blood might be shedding from polyps (1-2cm) or CRC. This test needs to be repeated several times to enhance sensitivity up to 90%. In CRC diagnosis, the scientist is concerned about the presence of hemoglobin, because it is the key component to identifying CRC by an immunohistochemical fecal occult blood test (FIT) [7]. It is often observed, colorectal adenocarcinomas show characteristic changes when the person has CRC; therefore the alteration of sDNA is a common phenomenon in CRC. However, limited applicability was seen in molecular diagnosis of CRC; hence, genetic and epigenetic tests have limited application in CRC diagnosis. Certain disadvantages of molecular diagnosis of CRC are the limited availability of biomarkers and the overall cost of molecular diagnosis is too costly [8].
Non-enzymatic Tumor Markers
It was often observed from the research that the tumour markers are propagated from tumour cells or the healthy cells when they start responding to tumours. However, marketed spurious non-enzymatic tumour markers are a big concern in CRC diagnosis. The best part about markers is, it helps to improve screening tests, prognosis, and examining CRC diagnosis process. By the proper histological images, the normal cells can be easily differentiated from benign tumour cells. In different body fluids, the markers can be assayed [9]. In Table 1, the various cancer antigens (CA), glycoproteins, and TAG-72, tissue polypeptide specific antigen (TPS) are highlighted. The metastasis phase can easily be evaluated when tumour markers’ expression is elevated. Tactlessly, available marketed markers have insufficient sensitivity towards CRC cells with limited organic specificity. Therefore, there is a prerequisite to have more sensitive biomarkers for CRC. Gastrointestinal tumours can be identified using CEA markers (5 μg/l). CEA is a glycoprotein that is propagated from the large intestine. The elevated CEA levels might be due to carcinogenesis. After the invasive operation, if CEA levels increase in the blood; that might be the symptoms of tumour recurrence. Noticeably, the elevation of CEA level in the blood occurs only when the patient has the last stage of cancer. Elevated CEA levels before surgical operation indicate adverse prognosis in a patient. In some cases, it was also observed that the patient would have advanced metastases with elevated CEA, but the clinical symptoms were obsolete; which helps to extend the survival time of a patient. Recent research also suggests that, even though the intestinal tumor expands, CRC levels are found missing in the blood. NNot only in CRC condition rather during inflammatory bowel disease and pancreatitis, the CEA elevation was reported. The presence of CEA is specific to CRC, but its sensitivity and accuracy were questionable in CRC recognition [10]. Another biomarker is CA 19-9; carbohydrate antigen, which was observed in the blood at an elevated concentration when a patient suffered from pancreatic or gastric colorectal cancer. The CA 19-9 can be a reliable marker in the diagnosis and monitoring of CRC. Like CEA, CA 19-9 also has less sensitivity in cancer diagnosis [11]. Nowadays, CA 19-9 and CEA are conjointly applied to evaluate tumor stage and viability. For the diagnosis and monitoring of the chemotherapeutic effect of gastrointestinal tumors, tissue polypeptide specific antigen (TPS) was estimated; which evolved during the S and G2 phase of mitosis. The concentration of TPS in serum was related to the neoplasm in cell proliferation. Hyperplasia can be recorded when an increased level of TPS was recorded. The elevated concentration of up to 60-70% can be seen in CRC patients. A study reveals that 75% of TPS levels were seen in patients who are suffering from colorectal cancer. It was also noticed that an initial high level of TPS reduces the time of survival rate for a colorectal cancer patient. Recent research findings also suggested that the presence of TPS estimation is more important than CEA monitoring. The elevated TPS level can also be seen in autoimmune disease and the most elevated level of TPS can be seen in patients who are suffering from post-alcoholic hepatitis. Another marker called TAG-72; tumor-associated glycoprotein, was produced by endothelial cells and gastric epithelial and bile ducts. There are other markers i.e., p-53, ras index, and thymidine phosphatase (TP), which have significant applications in CRC prognosis [12].
